Chevy Chase Trust Holdings LLC Sells 356 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Chevy Chase Trust Holdings LLC cut its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 0.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 40,975 shares of the medical instruments supplier’s stock after selling 356 shares during the period. Chevy Chase Trust Holdings LLC’s holdings in West Pharmaceutical Services were worth $16,214,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. BI Asset Management Fondsmaeglerselskab A S lifted its stake in shares of West Pharmaceutical Services by 68.7% during the first quarter. BI Asset Management Fondsmaeglerselskab A S now owns 3,309 shares of the medical instruments supplier’s stock valued at $1,309,000 after acquiring an additional 1,348 shares during the period. Central Pacific Bank Trust Division acquired a new position in shares of West Pharmaceutical Services during the first quarter valued at $483,000. Whittier Trust Co. of Nevada Inc. lifted its stake in shares of West Pharmaceutical Services by 5.2% during the first quarter. Whittier Trust Co. of Nevada Inc. now owns 19,822 shares of the medical instruments supplier’s stock valued at $7,843,000 after acquiring an additional 972 shares during the period. Whittier Trust Co. lifted its stake in shares of West Pharmaceutical Services by 4.0% during the first quarter. Whittier Trust Co. now owns 38,158 shares of the medical instruments supplier’s stock valued at $15,099,000 after acquiring an additional 1,458 shares during the period. Finally, Financial Counselors Inc. lifted its stake in shares of West Pharmaceutical Services by 1.1% during the first quarter. Financial Counselors Inc. now owns 11,441 shares of the medical instruments supplier’s stock valued at $4,527,000 after acquiring an additional 125 shares during the period. 93.90% of the stock is currently owned by institutional investors.

Insider Buying and Selling at West Pharmaceutical Services

In other West Pharmaceutical Services news, CEO Eric Mark Green sold 66,000 shares of the stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $366.65, for a total value of $24,198,900.00. Following the transaction, the chief executive officer now owns 152,908 shares of the company’s stock, valued at $56,063,718.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other West Pharmaceutical Services news, CEO Eric Mark Green sold 66,000 shares of the stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $366.65, for a total value of $24,198,900.00. Following the completion of the sale, the chief executive officer now directly owns 152,908 shares in the company, valued at $56,063,718.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Silji Abraham sold 1,800 shares of the stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $330.78, for a total value of $595,404.00. Following the completion of the sale, the senior vice president now owns 2,860 shares of the company’s stock, valued at $946,030.80. The disclosure for this sale can be found here. Insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Trading Up 3.4 %

Shares of WST traded up $11.06 during trading hours on Thursday, hitting $332.41. 18,187 shares of the stock traded hands, compared to its average volume of 530,321. The company has a current ratio of 2.61, a quick ratio of 1.95 and a debt-to-equity ratio of 0.03. West Pharmaceutical Services, Inc. has a 1-year low of $310.00 and a 1-year high of $415.73. The firm has a market capitalization of $24.21 billion, a PE ratio of 42.39, a price-to-earnings-growth ratio of 5.65 and a beta of 1.00. The business has a fifty day moving average of $335.13 and a 200-day moving average of $358.65.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, April 25th. The medical instruments supplier reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.29 by $0.27. West Pharmaceutical Services had a return on equity of 20.57% and a net margin of 19.42%. The firm had revenue of $695.40 million for the quarter, compared to analyst estimates of $670.62 million. During the same quarter in the prior year, the firm posted $1.98 earnings per share. The company’s quarterly revenue was down 3.0% on a year-over-year basis. Analysts expect that West Pharmaceutical Services, Inc. will post 7.76 EPS for the current year.

West Pharmaceutical Services Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, August 7th. Shareholders of record on Wednesday, July 31st will be paid a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.24%. The ex-dividend date of this dividend is Wednesday, July 31st. West Pharmaceutical Services’s payout ratio is 10.55%.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.